Could a protein derived from vitamin d tame chronic inflammation?
NCT ID NCT06877364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a protein called GcMAF, which is made from vitamin D-binding protein and is thought to calm the immune system. Researchers gave it to 120 adults with chronic inflammatory conditions like rheumatoid arthritis or cystitis that didn't improve with standard treatments. The goal was to check if it's safe and if it can reduce inflammation, measured by blood markers and disease activity scores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GcMAF (a protein derived from vitamin D-binding protein that activates immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with chronic inflammatory diseases who haven't responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not confirm effectiveness or safety in larger populations. The treatment is experimental and may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center For New Medical Technologies
Novosibirsk, Russia